Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Exp Neurol. 2021 Feb 4;339:113636. doi: 10.1016/j.expneurol.2021.113636

Figure 4. Human neurons lacking SARM1 are resistant to vincristine-mediated axon degeneration.

Figure 4.

(A) Representative images of sensory neuron axons at 48 hr post DMSO or vincristine treatments (5 nM). Scale bar, 100μm. (B) Axon degeneration post 48 hr DMSO or vincristine treatment (0.5, and 5 nM) was quantified. After vincristine treatment, significant axonal degeneration was observed in wild-type. This degeneration was delayed in SARM1 knockout axons. Kruskal-Wallis test, H=160.8 and p = 2.2 × 10−16, showed significant difference among groups (sample numbers are indicated on top of bars). Pairwise Wilcox comparison with Bonferroni adjusted p-value was used to calculate significant differences. *p < 5 × 10−4 denotes significant difference from the DMSO treated wild-type axons at a same dose.